Idiopathic Pulmonary Fibrosis – Epidemiology – Europe
DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of idiopathic pulmonary fibrosis for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's idiopathic pulmonary fibrosis forecast will answer the following questions:
Of all people with idiopathic pulmonary fibrosis, how many in each country have been formally diagnosed?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of idiopathic pulmonary fibrosis over the forecast period?
How many people with diagnosed idiopathic pulmonary fibrosis also have gastroesophageal reflux disease, pulmonary hypertension, emphysema, and/or obstructive sleep apnea?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following idiopathic pulmonary fibrosis patient populations:
Diagnosed prevalent cases.
Diagnosed prevalent cases with comorbid gastroesophageal reflux disease.
Diagnosed prevalent cases with comorbid emphysema.
Diagnosed prevalent cases with comorbid obstructive sleep apnea.
Idiopathic Pulmonary Fibrosis - Epidemiology - Europe
Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis per 100,000 Among People Aged 40+ in 2020 and 2030tttttttttttttt
Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis over the Next Ten Yearsttttttttttttttttt
Analysis of Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis Across the Countries Under Study in 2020 by GAP Stagesttttttttt
Number of Additional Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in 2030 Across the Countries Under Study Due to Trends in Risk or Survivalttttttttttttttttt
Diagnosed Prevalent Cases
Diagnosed Incident Cases
Diagnosed Prevalent Cases of IPF with Gastroesophageal Reflux Disease
Diagnosed Prevalent Cases of IPF with Pulmonary Hypertension
Diagnosed Prevalent Cases of IPF with Emphysema
Diagnosed Prevalent Cases of IPF with Obstructive Sleep Apnea
Drug-Treated Prevalent Cases
Studies Included in the Analysis of Idiopathic Pulmonary Fibrosis
Studies Excluded from the Analysis of Idiopathic Pulmonary Fibrosis
Risk/Protective Factors for Idiopathic Pulmonary Fibrosis
Alison Isherwood, M.Sc., M.Res., Ph.D.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.